Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus.
Summary of "Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus."
HISTORY AND CLINICAL
A 56-year-old woman presented with pronounced petechia. She complained about recurrent fever and night sweat for two weeks, having felt unwell during the past years.
Laboratory examinations showed thrombocytopenia, leukopenia and considerably elevated liver enzymes. Antinuclear antibodies and antibodies against double-stranded DNA were positive. Sonography showed a slightly enlarged liver with multiple surrounding lymph nodes, splenomegaly and chronic-atrophic thyroiditis. Gastroscopy revealed several polypes which were immunohistochemically classified as neuroendocrine tumors (NET). DIAGNOSIS, TREATMENT AND
Systemic lupus erythematosus (SLE) with involvement of several organs was diagnosed and high doses of steroids were given. The steroid was then gradually reduced and changed to azathioprine. The NET were removed endoscopically.
Neuroendocrine tumors are rare and localised to the stomach in only 2 - 4 %. Only three cases of gastric NET in the context of SLE with autoimmune gastritis have been reported so far in the literature.
Medizinische Klinik I, Klinikum am Steinenberg, Kreiskliniken Reutlingen gGmbH.
This article was published in the following journal.
Name: Deutsche medizinische Wochenschrift (1946)
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20812155
- DOI: http://dx.doi.org/10.1055/s-0030-1263306
Ascites in systemic lupus erythematosus (SLE) patients has a variety of etiologies, which usually require different treatment options. Our case was a 22-year-old patient with an unusual combination of...
The diagnosis of macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE) may be challenging as it can mimic the clinical features of the underlying disease or be confu...
There is currently no uniform definition of cutaneous lupus erythematosus (CLE) upon which to base a study population for observational and interventional trials. A preliminary questionnaire was deriv...
Transverse myelitis (TM) is a relatively infrequent but severe complication in systemic lupus erythematosus (SLE). Owing to its rarity and unfavorable outcome, we investigated its general features on ...
Lupus nephritis is a common and serious damage in systemic lupus erythematosus. The aim of our study is to define the frequency and to identify the predictors of lupus nephritis in patients with syste...
Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common...
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug mea...
OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus. II. Evaluate objective disease parameters, including serum complement levels...
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Medical and Biotech [MESH] Definitions
A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.